PAK1 inhibitors and uses thereof
US11065251B2 · kind B2 · utility
0Cited by
0References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 3, 2017 |
| Grant date | Jul 20, 2021 |
| Priority date | — |
| Expiry date | Feb 27, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using compounds that inhibit p21 protein (Cdc42/Rac)-activated kinase (PAK1).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.